Welcome to our dedicated page for Axim Biotechnologies news (Ticker: AXIM), a resource for investors and traders seeking the latest updates and insights on Axim Biotechnologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axim Biotechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axim Biotechnologies's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AXIM Biotechnologies has commenced the manufacturing of its proprietary Ocular Immunoglobulin E (IgE) and Lactoferrin diagnostic tests, fulfilling orders from its commercialization partner. The company is producing three separate lots of each assay with a monthly capacity of up to 25,000 units. These point-of-care tests deliver results in just eight minutes and can quantify IgE and Lactoferrin levels, aiding in the diagnosis and treatment of dry eye disease (DED). Approximately 344 million people globally are affected by DED, highlighting the demand for effective diagnostic tools. AXIM's ability to manufacture in-house enhances its quality control and profit margins. This milestone positions AXIM for a more rapid market entry of its diagnostic products and supports its ongoing collaboration with clinicians.
AXIM Biotechnologies has filed a provisional patent with the U.S. Patent and Trademark Office for a proprietary methodology in ocular diagnostic assays. This innovation enables the use of a significantly reduced tear sample size, improving the accuracy and usability of diagnostic tests. Most tests require a tear sample of about 10 microliters, while AXIM’s method only requires 1 microliter, enhancing test sensitivity and specificity. The company plans to integrate this technique into commercially available tests soon. AXIM is also focused on rapid diagnostic solutions for conditions like Dry Eye Disease, an area affecting millions of Americans.
FAQ
What is the current stock price of Axim Biotechnologies (AXIM)?
What is the market cap of Axim Biotechnologies (AXIM)?
